SecurityMRNS / Marinus Pharmaceuticals, Inc. (56854Q101)
CEOCashman Christopher Michael
IndustryPharmaceutical Preparations
Institutional Owners79
Institutional Shares26,039,659 - 64.26%
Common Stock Shares Outstanding40,525,013 shares (as of 2018-06-30)
Institutional Value$ 189,517,000 USD

Institutional Stock Ownership and Shareholders

MRNS / Marinus Pharmaceuticals, Inc. Institutional Ownership

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has 79 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 26,039,659 shares. Largest shareholders include Bain Capital Life Sciences Investors, Llc, Jennison Associates Llc, BlackRock Inc., Granite Point Capital Management, L.P., Franklin Resources Inc, Three Bays Capital Lp, Vanguard Group Inc, 683 Capital Management, LLC, Perceptive Advisors Llc, and Orbimed Advisors Llc.
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-14 13F-HR MILLENNIUM MANAGEMENT LLC 579,139 156,930 -72.90 2,212 1,109 -49.86
2018-08-15 13F-HR Verition Fund Management LLC 14,241 0 -100.00 54 0 -100.00
2018-08-14 13F-HR Cubist Systematic Strategies, LLC 0 12,683 0 90
2018-08-03 13F-HR Cable Hill Partners, LLC 6,000 2,000 -66.67 24 14 -41.67
2018-07-30 13F-HR Daiwa Securities Group Inc. 223 223 0.00 1 2 100.00
2018-08-13 13F-HR Granite Point Capital Management, L.P. Call 549,900 141,000 -74.36 2,101 997 -52.55
2018-08-13 13F-HR BlueMountain Capital Management, LLC 12,280 0 -100.00 47 0 -100.00
2018-08-14 13F-HR STATE STREET CORP 42,019 550,774 1,210.77 160 3,893 2,333.13
2018-08-14 13F-HR Shanda Payment Holdings Ltd. 10,000 10,000 0.00 38 71 86.84
2018-08-14 13F-HR MORGAN STANLEY 12,844 91,866 615.24 49 650 1,226.53
2017-02-10 13F-HR BlackRock Fund Advisors 86,253 101,703 17.91 157 103 -34.39
2018-05-11 13F-HR Delpha Capital Management, Llc 2,922 0 -100.00 24 0 -100.00
2018-08-10 13F-HR Cutler Group LP Put 28,700 5,300 -81.53 40 1 -97.50
2018-08-13 13F-HR GROUP ONE TRADING, L.P. 122,744 0 -100.00 469 0 -100.00
2018-08-14 13F-HR ORBIMED ADVISORS LLC 567,600 567,600 0.00 2,168 4,013 85.10
2018-08-14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 227,650 1,609
2018-08-15 13F-HR Krilogy Financial LLC 7,400 0 -100.00 28 0 -100.00
2018-08-14 13F-HR THREE BAYS CAPITAL LP 944,300 1,905,469 101.79 3,607 13,472 273.50
2018-08-14 13F-HR Marshall Wace North America L.P. 95,560 379,471 297.10 365 2,683 635.07
2018-08-14 13F-HR VANGUARD GROUP INC 1,301,219 1,573,281 20.91 4,971 11,123 123.76
2018-05-11 13F-HR CITIGROUP INC 1,277 178 -86.06 10 1 -90.00
2018-08-14 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 1,612 29,863 1,752.54 6 211 3,416.67
2018-08-10 13F-HR Legal & General Group Plc 5,421 38
2018-02-09 13F-HR RidgeWorth Capital Management LLC 37,803 308
2018-07-25 13F-HR BNP PARIBAS ARBITRAGE, SA 1,190 8,413
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 22,956 116,511 407.54 42 118 180.95
2018-08-13 13F-HR Granite Point Capital Management, L.P. 2,638,321 2,638,321 0.00 10,078 18,653 85.09
2018-08-10 13F-HR Quantitative Investment Management, LLC 161,900 1,144
2018-08-13 13F-HR HAP Trading, LLC 379,612 217,464 -42.71 1,450 1,537 6.00
2018-08-14 13F-HR AQR CAPITAL MANAGEMENT LLC 69,715 493
2018-08-09 13F-HR GSA CAPITAL PARTNERS LLP 0 19,900 0 141
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 28,396 4,458 -84.30 108 32 -70.37
2018-08-13 13F-HR VHCP Management II, LLC 345,240 2,441
2018-08-06 13F-HR STRS OHIO 10,700 75
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 406,191 0 -100.00 1,552 0 -100.00
2018-08-10 13F-HR Cutler Group LP Call 6,100 100 -98.36 0 0
2018-08-06 13F-HR RHUMBLINE ADVISERS 34,698 245
2018-08-14 13F-HR UBS Group AG 0 78,276 0 553
2018-08-13 13F-HR HAP Trading, LLC Put 625,000 250,000 -60.00 1,094 69 -93.69
2018-08-14 13F-HR New Leaf Venture Partners, L.L.C. 342,550 0 -100.00 1,309 0 -100.00
2018-08-14 13F-HR/A CITADEL ADVISORS LLC Call 16,300 60,300 269.94 62 426 587.10
2018-08-14 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 55,718 394
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 5,630 7,018 24.65 22 49 122.73
2018-08-13 13F-HR Renaissance Technologies LLC 420,400 420,400 0.00 1,606 1,606 0.00
2018-08-14 13F-HR Jefferies Group LLC 24,900 0 -100.00 95 0 -100.00
2018-07-26 13F-HR TCI Wealth Advisors, Inc. 400 3
2018-08-14 13F-HR Arrowpoint Asset Management, LLC 10,735 10,735 0.00 41 76 85.37
2018-08-13 13F-HR GROUP ONE TRADING, L.P. Call 101,900 148,500 45.73 389 1,050 169.92
2018-08-14 13F-HR Dynamic Technology Lab Private Ltd 0 51,289 0 363
2018-07-27 13F-HR PIEDMONT INVESTMENT ADVISORS LLC 632 4
2018-08-10 13F-HR VIRTUS ETF ADVISERS LLC 80,389 109,991 36.82 307 778 153.42
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 227,700 149,200 -34.48 870 1,055 21.26
2018-08-14 13F-HR BARCLAYS PLC 60,501 47,057 -22.22 232 333 43.53
2018-04-18 13F-HR/A FNY Partners Fund LP 22,500 0 -100.00 183 0 -100.00
2018-08-14 13F-HR Bain Capital Life Sciences Investors, Llc 3,977,453 3,977,453 0.00 15,194 28,121 85.08
2018-08-15 13F-HR/A GMT Capital Corp 1,266,899 0 -100.00 4,840 0 -100.00
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 259 2
2018-08-14 13F-HR Invesco Ltd. 13,035 18,582 42.55 50 131 162.00
2018-08-10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 25,800 182
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 164,060 270,032 64.59 626 1,909 204.95
2018-08-14 13F-HR Voya Investment Management LLC 13,747 97
2018-08-08 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 67,800 480
2018-08-14 13F-HR DekaBank Deutsche Girozentrale 17,000 17,000 0.00 60 120 100.00
2018-08-10 13F-HR CITIGROUP INC 178 4,053 2,176.97 1 29 2,800.00
2018-09-17 13F-HR/A 683 Capital Management, LLC 1,200,000 1,200,000 0.00 4,584 8,484 85.08
2018-08-13 13F-HR ALLIANCEBERNSTEIN L.P. 20,800 147
2018-09-18 13F-HR/A NORTHERN TRUST CORP 53,309 386,864 625.70 204 2,736 1,241.18
2018-08-02 13F-HR/A ALPS ADVISORS INC 58,801 416
2018-08-14 13F-HR CAXTON CORP 26,827 13,105 -51.15 102 93 -8.82
2018-07-19 13F-HR FRED ALGER MANAGEMENT INC 18,000 18,000 0.00 69 127 84.06
2018-08-07 13F-HR Trexquant Investment LP 0 14,465 0 102
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 279,000 268,300 -3.84 1,066 1,897 77.95
2018-08-14 13F-HR JP Morgan Chase & Co 97,716 106,203 8.69 373 751 101.34
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 16,729 35,526 112.36 64 251 292.19
2018-08-14 13F-HR BlueCrest Capital Management Ltd 32,487 0 -100.00 124 0 -100.00
2018-08-08 13F-HR AMERICAN INTERNATIONAL GROUP INC 23,718 168
2018-08-10 13F-HR Pacad Investment Ltd. 58,500 0 -100.00 207 0 -100.00
2018-08-14 13F-HR A.R.T. Advisors, LLC 43,828 0 -100.00 167 0 -100.00
2018-08-14 13F-HR TEACHERS ADVISORS INC 69,858 494
2018-08-14 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 0 57,606 0 407
2018-08-14 13F-HR Holistic Financial Partners 265 0 -100.00 1 0 -100.00
2018-08-13 13F-HR Ameritas Investment Partners, Inc. 3,474 25
2018-08-10 13F-HR Cutler Group LP 21,400 1,400 -93.46 81 9 -88.89
2018-05-15 13F-HR Iguana Healthcare Management, LLC 100,000 100,000 0.00 816 382 -53.19
2018-08-07 13F-HR IFP Advisors, Inc 200 200 0.00 1 1 0.00
2018-08-13 13F-HR GROUP ONE TRADING, L.P. Put 182,900 71,600 -60.85 699 506 -27.61
2018-08-13 13F-HR Catamount Wealth Management 500 3
2017-02-10 13F-HR BlackRock Investment Management, LLC 2,024 2,024 0.00 4 2 -50.00
2018-07-26 13F-HR REGIONS FINANCIAL CORP 4,085 29
2018-08-14 13F-HR CREDIT SUISSE AG/ 0 133,546 0 944
2018-08-14 13F-HR PERCEPTIVE ADVISORS LLC 907,732 907,732 0.00 3,467 6,417 85.09
2018-08-14 13F-HR Cormorant Asset Management, LLC 478,111 478,111 0.00 1,826 3,380 85.10
2018-08-14 13F-HR GOLDMAN SACHS GROUP INC 147,229 28,418 -80.70 562 201 -64.23
2018-08-14 13F-HR/A CITADEL ADVISORS LLC Put 25,900 33,800 30.50 99 239 141.41
2018-08-09 13F-HR BlackRock Inc. 635,838 2,650,612 316.87 2,429 18,740 671.51
2018-08-14 13F-HR DEUTSCHE BANK AG\ 340,382 63,972 -81.21 1,299 451 -65.28
2018-08-10 13F-HR DIMENSIONAL FUND ADVISORS LP 15,100 0 -100.00 58 0 -100.00
2018-08-13 13F-HR Quantbot Technologies LP 2,148 0 -100.00 8 0 -100.00
2018-08-14 13F-HR Capital Bank & Trust Co 4,120 4,120 0.00 16 29 81.25
2018-08-14 13F-HR Tower Research Capital LLC (TRC) 361 0 -100.00 1 0 -100.00
2018-08-10 13F-HR Artal Group S.A. 500,000 500,000 0.00 1,910 3,535 85.08
2018-08-13 13F-HR ProShare Advisors LLC 18,692 21,824 16.76 71 154 116.90
2018-07-30 13F-HR SIMPLEX TRADING, LLC 50,258 0 -100.00 191 0 -100.00
2018-08-14 13F-HR Sabby Management, LLC Call 451 1,268 181.15 172 896 420.93
2018-08-14 13F-HR FRANKLIN RESOURCES INC 1,667,585 1,928,085 15.62 6,370 13,632 114.00
2018-08-02 13F-HR JENNISON ASSOCIATES LLC 2,735,623 2,757,356 0.79 10,450 19,495 86.56
MRNS: Marinus Pharmaceuticals Analysis and Research Report

2018-04-27 - Asif

Overview Marinus Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. The company's clinical stage product candidate, ganaxolone, is a positive allosteric modulator of GABAA being developed in three different dose forms: intravenous (IV), capsule and liquid. The multiple dose forms are intended to maximize the therapeutic range of ganaxolone for adult and pediatric patient populations, in acute and chronic care, and both in-patient and self-administered settings. Ganaxolone exhibits anti-seizure, anti-anxiety and anti-depressive actions via its effects on synaptic and extrasynaptic GABAA receptors. The company's Pipeline Marinus Pharmaceuticals is developing ganaxolone to treat children suffering from rare epilepsies and both adults and children suffering from other neuropsychiatric conditions where there is a mechanistic rationale for ganaxolo...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

10 Killer Stocks to Buy That No One Knows About  

2018-08-06 investorplace
We have all heard about the big stocks a million times. That’s not to say they are bad investing prospects. Not at all. Amazon (NASDAQ:AMZN), for example, is an expensive stock with robust growth potential. (62-10)

GW Pharmaceuticals: Value Beyond Epidiolex?

2018-06-04 seekingalpha
GW has Sativex ready for a Phase 3 study in an indication that already has approval in several countries outside of the US. (120-0)

How To Use Probabilities In Investing: Open Sources

2018-05-11 seekingalpha
(In whose favor are the odds of this particular game, hmm? Image by Own work, CC BY-SA 3.0, source) (83-0)

BRIEF-Marinus Pharmaceuticals Reports Quarterly Loss Per Share $0.15

2018-05-02 reuters
* MARINUS PHARMACEUTICALS INC - AT MARCH 31, 2018, HAD CASH, CASH EQUIVALENTS AND INVESTMENTS OF $52.0 MILLION, COMPARED TO $58.4 MILLION AT DECEMBER 31, 2017 (71-0)

Ovid Therapeutics: Beaten Down IPO With Upcoming 2018 Catalysts

2018-05-01 seekingalpha
Data from the phase 2 STARS trial for OV101 in Angelman’s syndrome is expected in Q3, 2018. (204-0)

CUSIP: 56854Q101